Parabilis eyes $475m IPO to push lead asset into Phase III - Pharmaceutical Technology

Regeneron-backed Parabilis will use the funds from this IPO to progress its lead asset, zolucatetide, to Phase III in desmoid tumours. The Regeneron-partnered biotech is currently progressing its lead asset, zolucatetide, in desmoid tumours. Parabilis will use the funds to progress its first-in-class asset, zolucatetide, into a registrational trial for the treatment of desmoid tumours. Credit: good render / Shutterstock.com. Parabilis Medicines is hoping to raise $475m in an initial public offering (IPO) as it set its sights on the Nasdaq exchange. The proposed IPO will see Parabilis offer 25,000,000 shares at $18 per unit, which could see the company…

Source: Pharmaceutical Technology